Pradaxa and Spiriva generic in 2018!

Never any substance. Never any facts nor substance to back up your posts. It's all about you and your experiences. Completely ignores others and the reality they are facing. Ignore the rest of the country. You shouldn't feel very good about that. This person had it right:

Consider that $13K a down payment on your not to distant severance. You are either an idiot or destined for management if you feel comfortable with Stiolto's performance.

 

Wrong! Burgeoning market, growing steadily. Haters gonna hate!

 

yes the market is burgeoning and so is the doctors' hate for stiolto (and the crappy ass delivery system), so that is burgeoning as well. haters are gonna hate. lmao

 

Jelly? Why you so mad? You're a drug rep, get over yourself.

 

not mad. not a drug rep. over myself realistic

 

Do yourself a favor, don't waste any more years of your life on this mission. Find something else more productive and more fun to do. We are not stupid. If we choose to stay here it does not affect you, and if we choose to leave, it does not affect you. Go enjoy the long weekend and try to think about something else.

 

+1

What kind of loser do you have to be keep coming on here to sew your seeds of negativity. Anyone with an opinion that really matters is way too busy to make CP a priority. Those of us that sell this product and haven't left yet probably believe in it. We are going to go down swinging, if, that is IF, we can't make it work. This guy is major loser! A very small, insignificant person.

 

1. Launch date is irrelevant, its the patent application priority date, and typically 20 years of exclusivity.

2. The reason combivent did not have competitors is that the formulation is difficult. Not so with Spiriva.

3. Both spiriva and pradaxa are done in the next 12-18 months, period.

4. Empa will get killed by others in the SGLT2 space.

The only thing they have that will make some money is Ofev. It's over unless you want to get into the animal health business which will grow and do well under this administration.

-Mic Drop................

 

The original post is about Pradaxa coming off patent 2018, you dumbass.

 

Boy you are such an idiot. Launch dates are completely irrelevant, all that matters is when the patent was filed, wich always is many years before launch. This is why BI sux, because of remedial sales folks like you.

 

Heart Home > Generic Pradaxa
Boehringer Ingelheim Pharmaceuticals has the exclusive rights to manufacture Pradaxa (dabigatran) until February 2018. After the first patent for the medication expires, various other companies may manufacture a generic Pradaxa product. However, lawsuits or other patents for specific uses of the drug may delay the manufacturing of a generic product. Although dabigatran is the "generic name" for Pradaxa, it is not a generic version of it.

 

The BI sales force in not sustainable for more than another two years. No pipeline. They can have contract do a few drive-bys and drop samples with the crumbs that dont go generic beyond that.

 

completely agreed. Go to MyBi and look at the most recent US performance #s. 1/2 of our sales come from Spiriva and Pradaxa. When those 2 are gone in about 2 years, time for more layoffs. We need something in our pipeline, and at this point the only way to get something fast enough would be a purchase. Don't see it happening, so might want to start preparing everyone.

 

90 minute call on 11/16 to announce CV strategy for 2018. Predictions? I predict Q1 will be unchanged. CV will be gone in Q2.

 

Town Hall tells it all. Nothing left to sell. It's worth watching. We have time to look for another job, but no long-term future with BI. 2018 no CV, 2020 respiratory gone.

 

I agree!

 

What was the takeaway? Did they say how long it would be around....how long we would sell it ? I was in pto.